论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
Authors Li XL, Ren XY, Liang JM, Ma WJ, Wang ZH, Yang ZQ
Received 15 June 2017
Accepted for publication 25 August 2017
Published 19 September 2017 Volume 2017:12 Pages 6963—6972
DOI https://doi.org/10.2147/IJN.S144056
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Alexander Kharlamov
Peer reviewer comments 3
Editor who approved publication: Dr Linlin Sun
Abstract: Hemangioma is a common
benign tumor affecting infants. In this study, we prepared sodium morrhuate
immunoliposomes through encapsulation of sodium morrhuate with liposomes
coupled with an anti-VEGFR2/KDR antibody and examined its effect on the biology
of human hemangioma endothelial cells (HECs). It was found that compared to the
liposomal sodium morrhuate group, treatment with sodium morrhuate
immunoliposomes facilitated cell detachment and apoptotic death. Confocal
microscopy analysis revealed that sodium morrhuate immunoliposomes had a higher
binding activity to HECs than liposomal sodium morrhuate. Apoptosis analysis
further demonstrated that treatment with liposomal sodium morrhuate or sodium
morrhuate immunoliposomes significantly induced apoptosis in HECs, compared to
the control group. Western blot analysis revealed an induction of caspase-3 and
caspase-9 levels and reduction of caspase-8 and Bcl-2 levels in HECs treated
with liposomal sodium morrhuate or sodium morrhuate immunoliposomes. Taken
together, these results indicate that sodium morrhuate immunoliposomes have an
increased capacity to target HECs and promote mitochondrial apoptosis.
Therefore, sodium morrhuate immunoliposomes may represent a promising agent in
the treatment of hemangiomas.
Keywords: liposome,
hemangioma, VEGF2, KDR, apoptosis